Elitek Or Fasturtec Market Report 2026

Elitek Or Fasturtec Market Overview

• The Elitek Or Fasturtec market growth in the historic period has been driven by increasing chemotherapy usage, historical tls complication rates • Market expansion is supported by rising global cancer burden, expansion of pediatric oncology programs • Growth Driver: Rising Leukemia Prevalence Fuels Growth In The Market • Market Trend: Sanofi Expands Elitek's Application To Adult Patients With FDA Approval • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Elitek Or Fasturtec Market?

Elitek (known as Fasturtec outside the US) is a medication containing rasburicase, used to treat or prevent high uric acid levels caused by tumor lysis syndrome (TLS) in cancer patients undergoing chemotherapy. It works by converting uric acid into allantoin, which is more easily excreted by the kidneys, reducing the risk of kidney damage. It is administered intravenously and is important for patients with leukemia, lymphoma, or other malignancies that rapidly release uric acid during treatment. The main dosage forms in the elitek or fasturtec market are injectable and lyophilized powder. Elitek (rasburicase) injectable is a prescription medication used to manage high uric acid levels in the blood (hyperuricemia) caused by cancer treatments in patients with leukemia, lymphoma, or other malignancies. The various indications include tumor lysis syndrome (TLS) and other indications. The various types of patients include pediatric patients and adult patients, and several distribution channels including hospital pharmacies, retail pharmacies, and online pharmacies. The different end uses encompass hospitals, clinics, ambulatory care, and home care.

What Is The Elitek Or Fasturtec Market Growth Forecast?

The growth in the forecast period can be attributed to rising global cancer burden, expansion of pediatric oncology programs, improved early tls risk assessment, growth in specialty oncology centers, advancements in supportive cancer care. Major trends in the forecast period include rising focus on oncology supportive care, increased use in tumor lysis syndrome, growth in hospital based infusion therapies, expansion of pediatric oncology treatments, improved chemotherapy safety protocols.

What Are The Drivers Of The Elitek Or Fasturtec Market?

The rise in the prevalence of leukemia is expected to propel the growth of the elitek or fasturtec market going forward. Leukemia is attributed to the uncontrolled proliferation of abnormal white blood cells in the bone marrow, often caused by genetic mutations, environmental factors, or exposure to radiation and certain chemicals. Leukemia cases are rising due to factors such as aging populations, genetic predispositions, environmental exposures, and improved diagnostic capabilities. Elitek (Fasturtec) helps leukemia patients by reducing high uric acid levels caused by tumor lysis syndrome (TLS), a condition that occurs when cancer treatments rapidly destroy leukemia cells, releasing large amounts of uric acid into the bloodstream. For instance, in 2024, according to the American Cancer Society, a US-based non-profit cancer advocacy organization, the number of leukemia cases increased to 62,770, reflecting an increase from 59,610 recorded in 2023. Thus, the rise in the prevalence of leukemia is driving the elitek or fasturtec industry. The rise in healthcare expenditures is expected to propel the growth of the elitek or fasturtec market going forward. Health expenditures refer to all costs associated with providing health services, family planning activities, nutrition programs, and emergency help with a focus on health. Healthcare expenditures increased primarily because the rising prevalence of chronic diseases led to greater demand for continuous treatments, long-term medications, and frequent medical visits. Rising healthcare expenditures are useful for Elitek/Fasturtec as increased spending on oncology care and supportive treatments expands access to advanced therapies that manage tumor lysis syndrome, boosting demand for rasburicase in high-risk cancer patients. For instance, in May 2025, according to Statistics Netherlands, a Netherlands-based national statistical office, the Netherlands spent approximately 130.70 billion dollars on health care in 2024, which was 9.79 billion dollars or 8.1 percent more than in 2023. Therefore, the rise in healthcare expenditures is driving the growth of the elitek or fasturtec industry.

Key Players In The Global Elitek Or Fasturtec Market

Major companies operating in the elitek or fasturtec market are Sanofi S.A.

Global Elitek Or Fasturtec Market Trends and Insights

A key trend in the elitek or fasturtec market is the expanding focus on adult applications, particularly for the management of tumor lysis syndrome (TLS) in cancer patients. With the increasing prevalence of TLS among individuals undergoing chemotherapy for aggressive malignancies such as leukemia, lymphoma, and solid tumors, there is a growing demand for effective treatments to address this life-threatening condition. Companies in this space are working to broaden the use of their products beyond pediatric indications, targeting a wider range of cancer therapies. For instance, in October 2023, Sanofi S.A., a France-based pharmaceutical company, received FDA approval for Elitek for the initial management of plasma uric acid levels in adult patients with leukemia, lymphoma, and solid tumors undergoing anti-cancer therapy that may lead to tumor lysis syndrome (TLS) and elevated uric acid levels. This approval is supported by pivotal Phase 3 trial results demonstrating that Elitek significantly reduced plasma uric acid levels compared to the standard care of oral allopurinol in adults at risk for TLS, providing a critical treatment option for this potentially life-threatening condition.

What Defines the Elitek Or Fasturtec Market?

The elitek or fasturtec market consists of sales of supportive medications and combination therapy kits. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Elitek Or Fasturtec Market Report 2026?

The elitek or fasturtec market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the elitek or fasturtec industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.